Delisting riskPopularity #5,281
POAS · AMEX · Medical - Devices

Phaos Technology (POAS)

Builds optical microscopy systems for inspection, metrology and biology.

$0.1615
vs last close−0.01 (−4.44%)
Loading prices…

Phaos Technology Holdings (CaymPOAS
Health Care

Builds advanced optical microscopes and bundled analysis software for industrial inspection, metrology, biology and research, earning primarily from device and parts sales with maintenance support. The Cayman-listed parent owns the Singapore operating subsidiary, while core microsphere technology is licensed from NUS.

Designs and assembles advanced optical microscopy systems, centered on the OptoNano super-resolution platform and the PT-Industrial, PT-Metrology, PT-Biology, PT-Stereo and PT-Zoom ranges. Proprietary software supports instrument control, automation, data analysis and pattern recognition, but is bundled with hardware rather than sold separately. Sales are chiefly device and parts shipments, supplemented by maintenance contracts, to manufacturers, biomedical providers and research institutions.

Reaches customers directly and through distributors and consultants across Asian markets, while providing customized end-to-end systems. Operations depend on third-party components, an OEM supplier, in-house assembly and licensed NUS microsphere technology. Revenue is concentrated in a small customer base and recognizes after delivery and customer acceptance.

Company facts

CEOGan Hong Loon
ListedNov 13, 2025
ExchangeAMEX
HeadquartersSingapore, Singapore
CountrySingapore
Employees10
CIK0002024258
ISINKYG7049C1042

Market cap$2.3M
EPS (ttm)−$0.2017
P/E (ttm)−0.8379
ROE-364.1%
P/B0.5571
P/S28.29
Dividend yieldDiv yield
Beta0.33vs XLV 0.49

No analyst consensus on record.

Not reported.

Debt to equity8.50%
Current ratio400.60%

ProfitabilityRevenueNet incomeNet margin

Q2 FY25Q4 FY25
Revenue$53.4K$28.5K
Net income−$916.7K−$2.9M
Net margin0.0%0.0%

GrowthOperating income

Q2 FY25Q4 FY25
Operating income−$940.4K−$2.9M
YoY growth

Balance sheet, Apr 30, 2026Cash & short-term investments $597.4K · Total debt $353.5K · Total assets $4.1M · Shareholders' equity $4.2M

Revenue
$28.5K
Operating income
−$2.9M
Net income
−$2.9M

Reported in SGD, converted at the latest exchange rate

View details

No dividends on record.

Institutions5.35%732.7K shares
8 holders · as of Jun 30, 2026
Other94.65%12.97M shares
remainder

13.71M company shares as of Sep 15, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing

Top shareholders13F · 13D/G · Form 4

HolderStakeSharesDate
UBS Group AGInstitution
2.63%360,388as of Jun 30, 2026
Jane Street Group, LLCInstitution
0.89%121,941as of Jun 30, 2026
XTX Topco LtdInstitution
0.77%105,900as of Jun 30, 2026
Virtu Financial LLCInstitution
0.45%61,126as of Jun 30, 2026
Susquehanna International Group, LLPInstitution
0.24%32,559as of Jun 30, 2026

Insider tradesForm 4

Nothing filed in the last 12 months.

View details

  • Danaher

    Leica systems overlap in industrial inspection and biological microscopy.

  • Bruker

    Super-resolution bioimaging alternative for research microscopes.

Compare

CompanyPriceChange
Phaos Technology$0.1615−4.44%$2.3M28.3
Danaher$221.39+2.57%$151.67B38.325.06.0+5.5%
Bruker$61.580.00%$9.37B27.22.7+5.2%
Median38.326.14.4+5.3%